Autoimmune myasthenia gravis in childhood

Seminars in Neurology

Volumn 24, Issue 1, 2004, Pages 101-110

  Andrews, P Ian ^a,b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Juvenile myasthenia gravis; MuSK antibody; Seronegative; Thymectomy

Indexed keywords

ACETYLCHOLINESTERASE; ACETYLCHOLINESTERASE RECEPTOR ANTIBODY; ATROPINE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EDROPHONIUM CHLORIDE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MUSCLE SPECIFIC KINASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PHOSPHOTRANSFERASE; PREDNISOLONE; PYRIDOSTIGMINE; STEROID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTIGEN BINDING; ASYSTOLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BONE MINERALIZATION; BRADYCARDIA; CHILD; CHILDHOOD DISEASE; CHOLINERGIC CRISIS; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG SAFETY; ELECTROPHYSIOLOGY; ENZYME INHIBITION; FLU LIKE SYNDROME; FLUID RETENTION; GROWTH RETARDATION; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; IMMUNOASSAY; IMMUNOMODULATION; LEUKOPENIA; LONG TERM CARE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOPATHY; NAUSEA; NEUROMUSCULAR TRANSMISSION; PANCYTOPENIA; PATHOPHYSIOLOGY; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SUDDEN DEATH; SWEATING; TERATOGENESIS; THYMECTOMY; VOMITING;

ADJUVANTS, IMMUNOLOGIC; AGE FACTORS; AUTOANTIBODIES; CHILD; CHOLINESTERASE INHIBITORS; HUMANS; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC;

EID: 3042694394     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-829591     Document Type: Review

References (92)

1. Willis T. De Anima Brutorum. In: Portage S, ed. Two Discourses Concerning the Soul of Brutes. Translated by Pordage S. London, 1683 Oxford: Theatro Sheldoniano; 1672
2. Erb W. Zur casuistik der bulbaren lahmungen. (3) Ueber einen neuen, wahrscheinlich bulbaren symptomencomplex. Arch Psychiatr Nervenkr 1879;9:336-350
3. Kandel ER, Siegelbaum SA. Signaling at the nerve-muscle synapse: directly gated transmission. In: Kandel ER, Schwartz JH, Jessell TM, eds. Principals of Neuroscience, 4th ed. New York: McGraw-Hill; 2000:187-206
4. Sanes JR, Jessell TM. The formation and generation of synapses. In: Kandel ER, Schwartz JH, Jessell TM, eds. Principals of Neuroscience, 4th ed. New York: McGraw-Hill; 2000:1087-1114
5. Sanes JR, Lichtman JW. Development of the vertebrate neuromuscular junction. Annu Rev Neurosci 1999;22:389-442
6. Fidzianska A. Human ontogenesis II: development of the human neuromuscular junction. J Neuropathol Exp Neurol 1980;39:606-615
7. Hesselmans LFGM, Jennekens FGI, van den Ord CJM, Oestreicher AB, Gispen WH. A light and electron microscopical study of B-50 (GAP-43) in human intramuscular nerve and neuromuscular junctions during development. J Neurol Sci 1989;89:301-311
8. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368
9. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304-2311
10. Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2003;2:99-106
11. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978-1980
12. Sanders DB, Andrews PI, Howard JF Jr, Massey JM. Sero-negative myasthenia gravis. Neurology 1997;48(suppl 5): S40-S45
13. Yoshikawa H, Lennon VA. Acetylcholine receptor autoantibody secretion by thymocytes: relationship to myasthenia gravis. Neurology 1997;49:562-567
14. Yamamoto T, Vincent A, Ciulla TA, Lang B, Johnston I, Newsom-Davis J. Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM. Ann Neurol 1991;30:550-557
15. Plested CP, Tang T, Spreadbury I, Littleton ET, Kishore U, Vincent A. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology 2002;59:1682-1688
16. Bufler J, Pitz R, Czep M, Wick M, Francke C. Purified IgG from seropositive and seronegative patients with myasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptor channels. Ann Neurol 1998;43:458-464
17. Drachman DB. Myasthenia gravis: a model disorder of acetylcholine receptors. Res Publ Assoc Res Nerv Ment Dis 1987;65:65-82
18. Soliven BC, Lange DJ, Penn AS, et al. Seronegative myasthenia gravis. Neurology 1988;38:514-516
19. Evoli A, Bartoccioni E, Bartocchi AP, Scuderi F, Tonali P. Anti-AchR negative myasthenia gravis: clinical and immunological features. Clin Invest Med 1989;12:104-109
20. Karni A, Zisman E, Katz-Levy Y, et al. Reactivity of T cells from seronegative myasthenia gravis to T cell epitopes of the human acetylcholine receptor. Neurology 1997;48:1638-1642
21. Lu CZ, Lu L, Hao ZS, Xia DG, Qain J, Arnason BG. Antibody-secreting cells to acetylcholine receptor and to presynaptic membrane receptor in seronegative myasthenia gravis. J Neuroimmunol 1993;43:145-149
22. Ragheb S, Lisak RP. Immune regulation and myasthenia gravis. Ann N Y Acad Sci 1998;841:210-224
23. Drachman DB. Medical progress: myasthenia gravis. N Engl J Med 1994;330:1797-1810
24. Geh VS, Bradbury JA. Ocular myasthenia presenting in an 11-month-old boy. Eye 1998;12:319-320
25. Phillips LH, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology 1992;42:1888-1893
26. Andrews PI, Massey JM, Howard JFJ, Sanders DB, Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology 1994;44:1208-1214
27. Evoli A, Batocchi AP, Bartoccioni E, Lino MM, Minisci C, Tonali P. Juvenile myasthenia gravis with prepubertal onset. Neuromuscul Disord 1998;8:561-567
28. Batocchi AP, Evoli A, Palmisani MT, Lo Monaco M, Bartoccioni M, Tonali P. Early-onset myasthenia gravis: clinical characteristics and response to therapy. Eur J Pediatr 1990;150:66-68
29. Uono M. Clinical statistics of myasthenia gravis in Japan. Int J Neurol 1980;14:87-99
30. Chiu HC, Newsom-Davis J, Hsieh KH, Hung T. Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology 1987;37:1854-1857
31. Osserman KE. Myasthenia Gravis. New York: Grune & Stratton; 1958
32. Walsh FB, Hoyt WF. Chapter 9: Disorders of muscle. Clinical Ophthalmology. Baltimore: Williams & Wilkins; 1969:1242-1311
33. Brodsky MC, Baker RS, Hamed LM. Pediatric Neuroophthalmology. New York: Springer; 1996
34. Cogan DG. Myasthenia gravis: a review of the disease and a description of lid twitch as a characteristic sign. Arch Ophthalmol 1965;74:217-221
35. Linder A, Schalke B, Toyka KV. Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients. J Neurol 1997;244:515-520
36. Rodriguez M, Gomez MR, Howard FM Jr, Taylor WF. Myasthenia gravis in children: long-term follow-up. Ann Neurol 1983;13:504-510
37. Fukuyama Y, Suzuki M, Segawa M. Studies on myasthenia gravis in childhood. Paediatr Univ Tokyo 1970;18:57-68
38. Wong V, Hawkins BR, Yu YL. Myasthenia gravis in Hong Kong Chinese. 2. Paediatric disease. Acta Neurol Scand 1992;86:68-72
39. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 1987;505:472-499
40. Snead OC, Benton JW, Dwyer D, et al. Juvenile myasthenia gravis. Neurology 1980;30:732-739
41. Okun MS, Charriez CM, Bhatti MT, et al. Asystole induced by edrophonium following beta blockade. Neurology 2001;57:739-740
42. Afifi AK, Bell WE. Tests for juvenile myasthenia gravis: comparative diagnostic yield and prediction of outcome. J Child Neurol 1993;8:403-411
43. Younger DS, Worrall BB, Penn AS. Myasthenia gravis: historical perspective and overview. Neurology 1997;48 (suppl 5):S1-S7
44. Lennon VA. Serological diagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. In: Lisak RP, ed. Handbook of Myasthenia Gravis and Myasthenic Syndromes. New York: Marcel Dekker; 1994:149-164
45. Andrews PI, Massey JM, Sanders DB. Acetylcholine receptor antibodies in juvenile myasthenia gravis. Neurology 1993;43:977-982
46. Sanders DB, Stålberg EV. AAEM Minimonograph #25: single-fiber electromyography. Muscle Nerve 1996;19:1069-1083
47. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis. Ann N Y Acad Sci 1998;841:720-726
48. Lewis RA, Selwa JF, Lisak RP. Myasthenia gravis: immunological mechanisms and immunotherapy. Ann Neurol 1995;37(suppl 1):S51-S62
49. Edan G, Landgraf F. Experience with intravenous immunoglobulin in myasthenia gravis: a review. J Neurol Neurosurg Psychiatry 1994;57(suppl):55-56
50. Evoli A, Palmisani MT, Bartoccioni E, Padua L, Tonali P. High-dose intravenous immunoglobulin in myasthenia gravis. Ital J Neurol Sci 1993;14:233-237
51. Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD. Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma globulin. Arch Neurol 1993;50:837-840
52. Fasano MB. Risks and benefits of intravenous immunoglobulin treatment in children. Curr Opin Pediatr 1995;7:688-694
53. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47:674-677
54. Badurska B, Ryniewicz B, Strugalska H. Immunosuppressive treatment for juvenile myasthenia gravis. Eur J Pediatr 1992;151:215-217
55. Arsura E, Brunner NG, Namba T, Grob D. High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 1985;42:1149-1153
56. Sakano T, Hamasaki T, Kinoshita Y, Kihara M, Ueda K. Treatment for refractory myasthenia gravis. Arch Dis Child 1989;64:1191-1193
57. Tanaka J, Matsuzaki K, Arai H, Nagai T, Matsumoto Y, Okada S. Intermittent methylprednisolone pulse therapy for myasthenia gravis in childhood. No To Hattatsu 1994;26:14-19
58. Bocanegra TS, Castaneda MO, Espinoza LR, Vasey FB, Germain BF. Sudden death after methylprednisolone pulse therapy. Ann Intern Med 1981;95:122
59. McLuckie AE, Savage RW. Atrial fibrillation following pulse methylprednisolone therapy in an adult. Chest 1993;104:622-623
60. Panegyres PK, Squier M, Mills KR, Newsom-Davis J. Acute myopathy associated with large parenteral dose of corticosteroid in myasthenia gravis. J Neurol Neurosurg Psychiatry 1993;56:702-704
61. Andrews PI. A treatment algorithm for autoimmune myasthenia gravis in childhood. Ann N Y Acad Sci 1998;841:789-802
62. Seybold ME. Thymectomy in childhood myasthenia gravis. Ann N Y Acad Sci 1998;841:731-741
63. Evoli A, Batocchi AP, Lo Monaco M, et al. Clinical heterogeneity of seronegative myasthenia gravis. Neuromuscul Disord 1996;6:155-161
64. Verma PK, Oger JJ. Seronegative generalized myasthenia gravis: low frequency of thymic pathology. Neurology 1992;42:586-589
65. Blossom GB, Ernstoff RM, Howells GA, Bendick PJ, Glover JL. Thymectomy for myasthenia gravis. Arch Surg 1993;128:855-862
66. Frist WH, Thirumalai S, Doehring CB. Thymectomy for the myasthenia gravis patient: factors influencing outcome. Ann Thorac Surg 1994;57:334-338
67. Seybold ME, Howard FM, Duane DD, Payne WS, Harrison EG. Thymectomy in juvenile myasthenia gravis. Arch Neurol 1971;25:385-392
68. Campbell JR, Bisio JM, Harrison MW, Campbell TJ. Surgical treatment of myasthenia gravis in childhood. J Pediatr Surg 1983;18:857-861
69. Keynes G, Camb MD. Surgery of the thymus gland. Lancet 1954;1:1197-1202
70. Brearley S, Gentle TA, Baynham MI, Roberts KD, Abrams LD, Thompson RA. Immunodeficiency following neonatal thymectomy in man. Clin Exp Immunol 1987;70:322-327
71. Ramos SB, Garcia AB, Viana SR, Voltarelli JC, Falcao RP. Phenotypic and functional evaluation of natural killer cells in thymectomized children. Clin Immunol Immunopathol 1996;81:277-281
72. Rubinstein A, Pelet B, Schweizer V. Immunological decay in thymectomized infants. Helv Paediatr Acta 1976;30:425-433
73. Wells WJ, Parkman R, Smogorzewska E, Barr M. Neonatal thymectomy: does it affect immune function? J Thorac Cardiovasc Surg 1998;115:1041-1046
74. Masaoka A, Yamakawa Y, Niwa H, et al. Extended thymectomy for myasthenia gravis patients: a 20-year review. Ann Thorac Surg 1996;62:853-859
75. Nakamura H, Taniguchi Y, Suzuki Y, et al. Delayed remission after thymectomy for myasthenia gravis of the purely ocular type. J Thorac Cardiovasc Surg 1996;112:371-375
76. Schumm F, Wietholter H, Fateh-Moghadam A, Dichgans J. Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry 1985;48:332-337
77. Wilkins KB, Bulkley GB. Thymectomy in the integrated management of myasthenia gravis. Adv Surg 1999;32:105-133
78. Sanders DB, Howard JF, Johns TR, Campa JF. High-dose daily prednisone in the treatment of myasthenia gravis. In: Dau PC, ed. Plasmapheresis and the Immunobiology of Myasthenia Gravis. Boston: Houghton-Mifflin; 1979:289-306
79. Pascuzzi RM, Coslett B, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291-298
80. Kupersmith MJ, Moster M, Bhuiyan S, Warren F, Weinberg H. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol 1996;53:802-804
81. Lindberg C, Andersen O, Larsson S, Oden A. Remission rate after thymectomy in myasthenia gravis when the bias of immunosuppressive therapy is eliminated. Acta Neurol Scand 1992;86:323-328
82. Kerribjin KF, De Kroon PM. Effect on height of corticosteroid therapy in asthmatic children. Arch Dis Child 1968;43:556-561
83. Rees L, Greene SA, Adlard P, et al. Growth and endocrine function in steroid sensitive nephrotic syndrome. Arch Dis Child 1988;63:484-490
84. Lettgen B, Jeken C, Reiners C. Influence of steroid medication on bone mineral density in children with nephrotic syndrome. Pediatr Nephrol 1994;8:667-670
85. Palace J, Newsom-Davis J, Lecky B. The Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50:1778-1783
86. Cosi V, Lombardi M, Erbetta A, Piccolo G. Azathioprine as a single immunosuppressive drug in the treatment of myasthenia gravis. Acta Neurol (Napoli) 1993;15:123-131
87. Confavreux C, Saddier P, Grimaud J, Moreua TH, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis. Neurology 1996;46:1607-1612
88. Evoli A, Batocchi AP, Tonali P, Marciano M. Risk of cancer in patients with myasthenia gravis. Ann N Y Acad Sci 1998;841:742-745
89. Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993;681:539-551
90. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000;55:448-450
91. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998;51:912-913
92. Ciafaloni E, Massey JM, Sanders DB. An open label trial of mycophenolate mofetil in myasthenia gravis. Neurology 2001;56:97-99